Per the release, Autonomix intends to leverage the technology in its strategic therapeutic units to enhance value for its pipeline. "This transaction represents a significant step forward for the development and commercialization of our innovative technology platform and can potentially simplify our regulatory strategy, as the Apex 6 Generator is already FDA-cleared in pain management," stated President and CEO Brad Hauser. At the same time, Autonomix is a speculative enterprise. The company made its public ...